Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
June 22 2018 - 8:01AM
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced that multiple presentations related to Endocyte’s
PSMA-617 radioligand therapy will be presented at the 2018 Society
of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI)
being held from June 23rd - 26th, 2018 in Philadelphia, PA.
“We are pleased that our leading radio-ligand therapy (RLT)
platform, which includes 177Lu-PSMA-617, and 225Ac-PSMA-617, will
be prominently featured throughout the program at SNMMI,” said Mike
Sherman, president and CEO of Endocyte. “225Ac-PSMA-617 is an alpha
emitting RLT with the potential to expand the application of
PSMA-617, and has been examined in over 100 patients with
compelling response rates to date. We intend to provide more
details on our strategy to develop 225Ac-PSMA-617 in the second
half of 2018, including leveraging existing clinical data sets to
accelerate development.”
Key Presentations and Symposia at
SNMMI:
Endocyte’s
chief medical officer, Dr. Alison Armour, will provide an overview
of 177Lu-PSMA-617 development during the Emerging Technology
Session. |
|
|
|
Title: |
|
Updates on
177Lu-PSMA-617 |
When: |
|
Monday, June 25, 2018
at 3:00 p.m. – 5:00 p.m. EDT |
Session Title: |
|
CMIIT Emerging
Technologies – A look into the Future of Molecular Imaging and
Therapy |
Location: |
|
112AB (Pennsylvania
Convention Center) |
|
|
|
Professor
Mike Sathekge from the University of Pretoria will present data
from an investigator-sponsored trial of Endocyte’s alpha-emitting
radioligand therapy 225Ac-PSMA-617. |
|
|
|
Abstract #: |
|
530 |
Title: |
|
Targeted Alpha Therapy
of mCRPC with 225Actinium-PSMA617: Dosimetry, toxicity and duration
of tumor-control |
When: |
|
Tuesday, June 26, 2018
at 10:00 a.m. – 11:30 a.m. EDT |
Session Title: |
|
SS62: Prostate:
Therapy |
Location: |
|
107AB (Pennsylvania
Convention Center) |
|
|
|
SNMMI will
also host an all-day pre-meeting categorical seminar on
PSMA-targeted radioligand therapies, including therapies using
Endocyte’s PSMA-617. |
|
|
|
Title: |
|
CAT 3: PSMA Radioligand
Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by
PSMA PET/CT. The Power of Precision Oncology |
When: |
|
Saturday, June 23, 2018
from 7:30 a.m. – 3:00 p.m. EDT |
Location: |
|
114 Michael A. Nutter
Theatre (Pennsylvania Convention Center) |
Several other discussions and posters covering
PSMA-617 will be presented at the 2018 SNMMI. For a complete list
of presentations, please visit the SNMMI Annual Meeting’s web
schedule at https://webmobile.experientengage.com/~SNM181/#/
Website Information
Endocyte routinely posts important information
for investors on its website, www.endocyte.com, in the “Investors
& News” section. Endocyte uses this website as a means of
disclosing material information in compliance with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the “Investors & News” section of Endocyte’s website,
in addition to following its press releases, SEC filings, public
conference calls, presentations and webcasts. The information
contained on, or that may be accessed through, Endocyte’s website
is not incorporated by reference into, and is not a part of, this
document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company's drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte's lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617,
entering phase 3 for metastatic castration-resistant prostate
cancer (mCRPC). Endocyte also expects to have an Investigational
New Drug application submitted in the fourth quarter of 2018 for
its adaptor-controlled CAR T-cell therapy which will be initially
studied in osteosarcoma. For additional information, please visit
Endocyte's website at www.endocyte.com.
Forward Looking Statements:
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company's
future development plans and presentation and status of clinical
data. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Factors that may cause such a difference include risks that the
company or independent investigators may experience delays in
submission and review of regulatory applications, execution of
clinical trials and/or the processing of clinical data. More
information about the risks and uncertainties faced by Endocyte,
Inc. is contained in the company’s periodic reports filed with the
Securities and Exchange Commission. Endocyte, Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contact:Michael Schaffzin, Stern
Investor Relations, Inc., (212) 362-1200, michael@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Sep 2023 to Sep 2024